The idea of cultured meat is not new and it has long been around, although there have not been the techniques to produce it until recently. Cultured meat was seemingly first mentioned in 1897 within a science fiction novel titled Auf Zwei Planeten, and further mentioned within a number of other novels throughout the 19th century.
Organizations Who are Conducting Human Trials with iPSC-Derived Cellular Therapeutics
Induced pluripotent stem (iPS) cells are a type of stem cell that can be generated directly from adult cells. They were first developed in 2006 by Shinya Yamanaka and his team. iPS cells are engineered by reprogramming adult cells, such as skin cells, to revert to a pluripotent state, meaning they have the ability to differentiate into any cell type in the body. This reprogramming is typically achieved by introducing a combination of specific genes or gene factors into the adult cells, which resets their developmental clock. [Read more…]
BlueRock Therapeutics exercises exclusive option to license iPSC cell therapy candidate OpCT-001 for treating Primary Photoreceptor Diseases from FUJIFILM Cellular Dynamics and Opsis Therapeutics
First iPSC therapy candidate to be licensed from the strategic R&D collaboration forged between BlueRock, FUJIFILM Cellular Dynamics, and Opsis Therapeutics in 2021
Primary photoreceptor diseases affect the structure and function of the photoreceptor cells in the retina, leading to irreversible vision loss in children and adults
IND filing for OpCT-001 is planned for 2024
INCELL Pioneering the World’s First Effective Cell Therapy for ALS
San Antonio, Texas, July 25, 2024 – ALS, or amyotrophic lateral sclerosis, is defined by the ALS Association (als.org) as a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. ALS symptoms vary and patients may lose the ability to speak, eat, move and breathe. There is no cure. The Mayo Clinic reports (mayoclinic.org) that no treatments can reverse ALS damage, but they may slow the progression of disease symptoms or help prevent complications. INCELL is committed to tackling innovative ALS therapy. [Read more…]
CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers
Another Patent Granted for CytoMed’s Allogeneic Induced Pluripotent Stem Cell (“iPSC”)-derived Hybrid Gamma Delta Natural Killer T (γδ NKT) cells technology
SINGAPORE, July 17, 2024 — CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the treatment of various cancers and aging-related diseases, has, through its wholly owned subsidiary, IPSC Depository Sdn Bhd acquired the licence and certain assets of Cellsafe International Sdn Bhd (In Liquidation) (“CISB”), a Malaysian cord blood bank for a cash consideration of approximately RM 2.3 million or US$ 490,000 to be funded from internal cash resources. [Read more…]
- « Previous Page
- 1
- …
- 95
- 96
- 97
- 98
- 99
- …
- 338
- Next Page »